Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 50 , ISSUE 2 ( April-June, 2016 ) > List of Articles

REVIEW ARTICLE

Bisphosphonates in Orthopedics: Evidence-based Review of Indications and Adverse Effects

Nitesh Gahlot, Uttam Chand Saini

Citation Information : Gahlot N, Saini UC. Bisphosphonates in Orthopedics: Evidence-based Review of Indications and Adverse Effects. J Postgrad Med Edu Res 2016; 50 (2):75-85.

DOI: 10.5005/jp-journals-10028-1197

Published Online: 00-06-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Aggarwal S, Gahlot N, Saini UC, Dhillon MS. Bisphosphonates in Orthopedics: Evidencebased Review of Indications and Adverse Effects. J Postgrad Med Edu Res 2016;50(2):75-85.


PDF Share
  1. Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders. Expert Opin Pharmacother 2002 Nov;3(11):1643-1656.
  2. Pharmacology of bisphosphonates. Bone 2011 Jul;49(1):42-49.
  3. Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 2008 Oct;22(5):831-847.
  4. Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2008 Sep;4(9):514-523.
  5. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 2002 Jul;17(7):1139-1147.
  6. Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother 2000 Jan;1(2):225-238.
  7. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am 2005 Jul;87(7):1609-1618.
  8. Use of bisphosphonates in orthopedic surgery. Orthopade 2008 Jun;37(6):595-613.
  9. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998 Apr;13(4):581-589.
  10. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis Int 2008;19(6):733-759.
  11. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010 Apr;95(4):1555-1565.
  12. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004 Mar 18;350(12):1189-1199.
  13. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Longterm Extension (FLEX): a randomized trial. JAMA 2006 Dec 27;296(24):2927-2938.
  14. Use of bisphosphonates in orthopedic surgery: pearls and pitfalls. Orthop Clin North Am 2014 Jul;45(3):403-416.
  15. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008 Apr;19(4):399-428.
  16. Glucocorticoidinduced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18(10):1319-1328.
  17. Alendronate for the treatment of osteoporosis in men. Expert Opin Pharmacother 2008;9: 491-498.
  18. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000 Aug 31;343(9):604-610.
  19. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007 May 3;356(18):1809-1822.
  20. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007 Nov 1;357(18):1799-1809.
  21. Shin splints: an unexpected effect of bisphosphonates in osteogenesis imperfecta. Clin Nucl Med 2009 Feb;34(2):87-88.
  22. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010 May 13;362(19):1761-1771.
  23. Antitumor effects of bisphosphonates. Cancer 2003 Feb 1;97(3 Suppl):840–847.
  24. The antitumor potential of bisphosphonates. Semin Oncol 2002 Dec;29(6 Suppl 21):33-42.
  25. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001 Mar 15;61(6):2602-2608.
  26. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998 Dec;16(12):3890-3899.
  27. Bisphosphonates: mechanisms of action. Endocr Rev 1998 Feb;19(1):80-100.
  28. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969 Sep 19;165(899): 1264-1266.
  29. Bone marrow cells in the ‘premetastatic niche’: within bone and beyond. Cancer Metastasis Rev 2006 Dec;25(4):521-529.
  30. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010 Aug 1;28(22): 3582-3590.
  31. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 2001 Apr;28(2 Suppl 6):35-44.
  32. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008 Mar;19(3):420-432.
  33. Longterm efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004 Jun 2;96(11):879-882.
  34. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebocontrolled trial. Cancer 2004 Jun 15;100(12):2613-2621.
  35. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 2009 Jul;45(11):1909-1915.
  36. Bisphosphonates in oncology. Bone 2011 Jul;49(1):71-76.
  37. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001 Jan 15;19(2):558-567.
  38. Bisphosphonate therapy for fibrous dysplasia. Pediatr Endocrinol Rev 2007 Aug;4(Suppl 4):440-445.
  39. Pamidronate for fibrous dysplasia due to McCune Albright Syndrome. Indian Pediatr 2010 Jul 7;47(7):633-635.
  40. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2006 May;19(Suppl 2):583-593.
  41. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002;15 (Suppl 3):929-937.
  42. Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia. J Clin Densitom 2001 Summer;4(2):167-172.
  43. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 2003 Oct;88(10):4569-4575.
  44. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 2000 Sep;137(3):403-409.
  45. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res 2001 Jan;382:6-12.
  46. Oral bisphosphonates in polyostotic fibrous dysplasia. Indian Pediatr 2003 Sep;40(9):894-846.
  47. Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthop 2006 Apr;77(2):177-197.
  48. Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis. J Bone Joint Surg Am 2005 Feb;87(2):293-301.
  49. Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients. Acta Orthop 2007 Dec;78(6):795-799.
  50. Zoledronic acid causes enhancement of bone growth into porous implants. J Bone Joint Surg Br 2005 Mar;87(3):416-420.
  51. The Otto Aufranc Award: bone augmentation around and within porous implants by local bisphosphonate elution. Clin Orthop Relat Res 2005 Dec;441:30-39.
  52. The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. J Bone Joint Surg Am 2003 Nov;85(11):2121-2126.
  53. WITHDRAWN: Pharmacological interventions for treating acute heterotopic ossification. Cochrane Database Syst Rev 2010(5):CD003321.
  54. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005 Apr;39(4):668-677.
  55. Heterotopic ossification revisited. Orthopedics 2011 Mar;34(3):177.
  56. Prevention of heterotopic ossification in cases of hypertrophic osteoarthritis submitted to total hip arthroplasty. Etidronate or Indomethacin? J Musculoskelet Neuronal Interact 2010 Jun;10(2):159-165.
  57. The use of eidronate disodium in the prevention of heterotopic ossification in burn patients. Burns 2008 May;34(3):355-360.
  58. Pharmacological interventions for treating acute heterotopic ossification. Cochrane Database Syst Rev 2004(4):CD003321.
  59. Clinical effect of etidronate disodium (EHDP) on heterotopic ossification following total hip arthroplasty. Osaka City Med J 1995 Dec;41(2):63-73.
  60. Myositis ossificans circumscripta of the knee improved by alendronate. Joint Bone Spine 2004 Mar;71(2):144-146.
  61. The influence of alendronate on bone formation and resorption in a rat ectopic bone development model. J Periodontol 2003 Jan;74(1):44-50.
  62. Progressive osseous heteroplasia controlled by intravenous administration of pamidronate. Am J Med Genet A 2006 Apr15;140(8):910-913.
  63. Aminobisphosphonates in heterotopic ossification: first experience in five consecutive cases. Spinal Cord 2005 Oct;43(10):604-610.
  64. Risedronate: a possible treatment for extraosseous calcification. Clin Calcium 2005 Sep;15(Suppl 1):75-78.
  65. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996 Oct;101(4):341-348.
  66. Complex regional pain syndrome: a review. Ann Vasc Surg 2008 Mar;22(2):297-306.
  67. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis 1997 Mar;56(3):201-204.
  68. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. Arthritis Rheum 2004 Nov;50(11):3690-3697.
  69. What is the place of diphosphonates in the treatment of complex regional pain syndrome I? Ann Readapt Med Phys 2005 Apr;48(3):150-157.
  70. Bisphosphonates for pain relief in reflex sympathetic dystrophy? Lancet 1997 Oct 18;350(9085):1117
  71. The successful use of pamidronate in an 11-year-old girl with complex regional pain syndrome: response to treatment demonstrated by serial peripheral quantitative computerised tomographic scans. Bone 2010 Apr;46(4):885-888.
  72. Treatment of complex regional pain syndrome: a review of the evidence. Can J Anaesth. 2010 Feb;57(2):149-166.
  73. Bisphosphonates in orthopedic applications. Bone 2011 Jul;49(1):95-102.
  74. The use of bisphosphonate in the treatment of avascular necrosis: a systematic review. Clin Rheumatol 2008 Jun;27(6):685-688.
  75. Nicolas Andry award. The biology of osteonecrosis of the human femoral head and its clinical implications: 1. Tissue biology. Clin Orthop Relat Res 1979 Jan-Feb(138):284-309.
  76. Pharmacotherapeutic aspects of femoral head necrosis. Orthopade 2007 May;36(5):446-450.
  77. Alendronate prevents collapse in mechanically loaded osteochondral grafts: a bone chamber study in rats. Acta Orthop Scand 2004 Dec;75(6):756-761.
  78. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 2005 Oct;87(10):2155-2159.
  79. Diagnosis and treatment of bone marrow edema syndrome of the hip and differential diagnosis from avascular necrosis of femoral head. Zhongguo Gu Shang 2009 Sep;22(9):697-699.
  80. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. Osteoporos Int 2005 Dec;16(12):2063-2068.
  81. Fractures in the collegiate athlete. Am J Sports Med 2004 Mar;32(2):446-451.
  82. Quantification of metaphyseal modeling in children treated with bisphosphonates. Bone 2005 Jun;36(6):999-1002.
  83. The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Bone 2004 Aug;35(2):418-424.
  84. Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats. J Orthop Res 2007 Aug;25(8):1070-1077.
  85. Treatment of stress fractures in athletes with intravenous pamidronate. Clin J Sport Med 2005 Mar;15(2):92-94.
  86. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am 2005 Mar;87(3):550-557.
  87. Zoledronic acid improves femoral head sphericity in a rat model of perthes disease. J Orthop Res 2005 Jul;23(4):862-868.
  88. Use of bisphosphonates in a case of Perthes disease. Orthop Nurs 2005 Nov-Dec;24(6):393-398.
  89. Bisphosphonate-modified gold nanoparticles: a useful vehicle to study the treatment of osteonecrosis of the femoral head. Nanotechnology 2011 Jan 21;22(3):035102
  90. Esophagitis associated with the use of alendronate. N Engl J Med 1996 Oct 3;335(14):1016-1021.
  91. The clinical tolerability profile of alendronate. Int J Clin Pract (Suppl) 1999 Apr;101:51-61.
  92. The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opin Drug Saf 2002 May;1(1):71-78.
  93. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007 Nov-Dec;5(10):475-482.
  94. Pharmacovigilance study of alendronate in England. Osteoporos Int 2003 Jul;14(6):507-514.
  95. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002 Aug;47(8):1665-1678.
  96. Nitrogenbisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001 Feb;59(2):193-202.
  97. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 2000 Sep;45(9):1792-1801.
  98. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998 Jun;16(6):2038-2044.
  99. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 2000 Jan;15(1):147-154.
  100. Statins prevent bisphosphonateinduced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004 Feb;19(2):278-288.
  101. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003 Sep;61(9):1115-1117.
  102. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004 May;62(5):527-534.
  103. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006 May 16;144(10):753-761.
  104. J Oral Maxillofac Surg 2007 Mar;65(3):369-376.
  105. Bisphosphonates and osteonecrosis: potential treatment or serious complication? Orthop Clin North Am 2009 Apr;40(2):223-234.
  106. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008 Jun;23(6):826-836.
  107. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007 Jul 4;99(13):1016-1024.
  108. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005 Apr 18;182(8):417-418.
  109. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005 Feb;34(2):120-123.
  110. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005 Jul 7;353(1):99-102.
  111. Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A casecontrolled study. BMC Musculoskelet Disord 2011;12:71
  112. Alendronate and atrial fibrillation. N Engl J Med 2007 May 3;356(18): 1895-1896.
  113. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord 2009;10(1):113
  114. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract 2010 May;64(6):821-826.
  115. Bisphosphonates and the risk of atrial fibrillation. Endokrynol Pol 2011 Jan-Feb;62(1):93-96.
  116. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Osteoporos Int 2012 Jan;23(1):247-254.
  117. Atrial fibrillation and the use of oral bisphosphonates. Ther Clin Risk Manag 2011;7:131-144.
  118. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int 2012 Jan;23(1):233-245.
  119. Zoledronic acid and atrial fibrillation in cancer patients. Support Care Cancer 2011 Mar;19(3):425-430.
  120. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol 2010 Nov 20;28(33):4898-4905.
  121. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcif Tissue Int 2010 May;86(5):335-342.
  122. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 2010 Jan;25(1):2-10.
  123. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;341:c4444
  124. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010 Aug 11;304(6):657-663.
  125. Oral bisphosphonates and oesophageal cancer. BMJ 2010;341:c4506
  126. Bisphosphonates and oesophageal cancer risk: where are we now? Maturitas 2011 Feb;68(2):106-108.
  127. Bisphosphonates and esophageal cancer--a pathway through the confusion. Nat Rev Rheumatol 2011 Jun;7(6):369-372.
  128. Prolonged bisphosphonate use linked to rare fractures, esophageal cancer. JAMA 2010 Nov 17;304(19): 2114-2115.
  129. Bisphosphonates in metastatic bone disease: renal safety matters. Oncologist 2005;10(Suppl 1):1-2.
  130. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 2011 Apr 16;71(6): 791-814.
  131. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis. Med Oncol 2010 Jun;27(2):224-229.
  132. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 2009 Feb;122(2 Suppl):S22-S32.
  133. Renal function and bisphosphonate safety. J Bone Miner Res 2008 Mar;23(3):453-454.
  134. Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women. Kidney Int 2008 Sep;74(5):557-559.
  135. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. Med Oncol 2008;25(3):356-359.
  136. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008 Sep;74(5):641-648.
  137. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007 May 3;356(18):1809-822.
  138. Safety and efficacy of risedronate in patients with agerelated reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005 Dec;20(12):2105-2115.
  139. Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease. Clin Drug Investig 2003;23(11):707-716.
  140. Renal safety of ibandronate. Oncologist 2005;10 (Suppl 1):14-18.
  141. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010 Feb;72(2):161-168.
  142. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006 Jan;61(1):31-33.
  143. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007 Jul-Aug;30(7):590-597.
  144. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab 2007;25(5):333-336.
  145. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009 Aug;20(8):1353-1362.
  146. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008 May-Jun;22(5):346-350.
  147. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008 Mar 20;358(12):1304-1306.
  148. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008 Feb;39(2):224-231.
  149. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008 Jul 17;359(3):317
  150. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006 Nov 9;355(19): 2048-2050.
  151. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on longterm treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009 Oct;24(10):1736-1740.
  152. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am 2011 Jul 6;93(13):1235-1242.
  153. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009 Nov;91(11):2556-2561.
  154. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium. Int J Rheum Dis 2009 Jul;12(2):149-154.
  155. Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures–a case report. Acta Orthop 2011 Jun;82(3):380-382.
  156. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008 Aug;93(8):2948-2952.
  157. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 2007 May-Jun;20(3):186-190.
  158. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol 2009 Mar;29(2):144-155.
  159. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000 Apr;15(4):613-620.
  160. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009 Jun;24(6):1095-1102.
  161. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005 Mar;90(3):1294-1301.
  162. Effect of inappropriate and continuous therapy with alendronate for ten years on skeletal integrity–observations in two elderly patients. J Endocrinol Invest 2008 Mar;31(3):251-254.
  163. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011 May 5;364(18):1728-1737.
  164. Bisphosphonate-related subtrochanteric femoral fractures. Am J Geriatr Pharmacother 2011 Jun;9(3):194-198.
  165. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011 May 1;48(5):966-971.
  166. What do we know about atypical femoral fractures? Insights and enigmas. Joint Bone Spine 2011 Dec;78(6):568-571.
  167. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep 2010 Mar;8(1):34-39.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.